NET PROFIT (x1000 DKK)
EMPLOYEES
Oblique Therapeutics AB (publ)
Closing information (x1000 DKK)
| Closing information | 2023/12 | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
40
|
1,359
|
204 |
| Earnings before taxes |
-41,596
|
-35,782
|
-44,820 |
| EBITDA |
-25,366
|
-32,230
|
-42,353 |
| Total assets |
12,467
|
12,146
|
22,422 |
| Current assets |
10,860
|
5,417
|
16,215 |
| Current liabilities |
4,112
|
7,525
|
6,947 |
| Equity capital |
7,784
|
2,247
|
14,344 |
| - share capital |
1,226
|
507
|
552 |
| Employees (average) |
18
|
18
|
16 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Solvency |
62.4%
|
18.5%
|
64.0% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-333.3%
|
-283.4%
|
-199.0% |
| Current ratio |
264.1%
|
72.0%
|
233.4% |
| Return on equity (ROE) |
-534.4%
|
-1592.4%
|
-312.5% |
| Change turnover | |||
| Change turnover % | -100% | ||
| Chg. No. of employees | |||
| Chg. No. of employees % |
13%
|
33% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.